Drug intelligence / Profile preview

retinoic acid + triamcinolone acetonide

Development stage: Preclinical
Modality: Small Molecules
Administration: Topical

Overview

Retinoic acid + triamcinolone acetonide is a combination medication that pairs a retinoid (retinoic acid/tretinoin) with a medium-potency corticosteroid (triamcinolone acetonide). This combination leverages complementary mechanisms of action: triamcinolone acetonide provides anti-inflammatory effects by suppressing inflammatory responses, while retinoic acid promotes cell turnover and may prevent corticosteroid-induced skin atrophy. The combination has shown enhanced efficacy in treating various inflammatory skin conditions and oral lesions compared to triamcinolone acetonide alone.

Other names: TARAtretinoin + triamcinolone acetonide

Targets

GR (Glucocorticoid receptor)RARA (Retinoic acid receptor alpha)

Beyond the preview

Go deeper on retinoic acid + triamcinolone acetonide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on retinoic acid + triamcinolone acetonide.

Explore the full profile